Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Spondyloarthritis encompasses a group of common inflammatory diseases caused by an overactive immune response affecting up to half a million people in the UK alone.

Model for role of GM-CSF in spondyloarthritis chronic inflammation. GM-CSF is produced by joint-resident innate lymphoid cell (ILC) and infiltrating CD4 T cells and acts to activate monocytes to produce other molecules that propagate the inflammatory response.
Model for role of GM-CSF in spondyloarthritis chronic inflammation. GM-CSF is produced by joint-resident innate lymphoid cell (ILC) and infiltrating CD4 T cells and acts to activate monocytes to produce other molecules that propagate the inflammatory response.

In collaboration with the Wellcome Trust Centre for Human Genetic, NDORMS researchers have been working to establish the type of disease-causing immune cells in this condition in order to identify new treatments. Spondyloarthritis encompasses a group of common inflammatory diseases thought to be driven by IL-17A-secreting type-17 lymphocytes.

In a recent article published in Nature Communications the researchers identified the expansion of a subset of immune cells in patient blood and joint fluid that are likely to be driving the inflammation by releasing a particular inflammatory molecule called GM-CSF.  Both GM-CSF+ and IL-17A  cells express increased levels of GPR65, a proton-sensing receptor associated with spondyloarthritis. Silencing GPR65 in primary CD4 T cells reduces GM-CSF production. GM-CSF and GPR65 may thus serve as targets for therapeutic intervention of spondyloarthritis.

Commenting on the findings, lead researcher Dr Hussein Al-Mossawi says: “It is hoped that this research will inform new trials that target GM-CSF in order to treat patients who suffer from this disease.”

Read the full article on Nature Communications:

 The research is funded by the Wellcome Trust and the National Institute for Health Research (NIHR).

Funding Bodies

NIHR NHS_Logo_Funded by Stamp.jpg

wellcome_trust_logo.png

Similar stories

New Botnar Research Institute Director starts today

Professor Jonathan Rees begins his new role as Director of the Botnar Research Institute today, taking over from Professor Andrew Carr.

Patient and public involvement in Rheumatology research – embracing the wave of change

On launching the new OPEN ARMS PPI group in Oxford, Dr. Laura Coates explored the patient and public involvement (PPI) models of three academic centres in the UK to show how it benefits researchers, clinicians, and patients alike.

Neutrophil molecular wiring revealed: transcriptional blueprint of short-lived cells

Researchers publish the first blueprint of transcriptional factors that control neutrophil-driven inflammation in Nature Immunology.

NDORMS joins research partnership to understand links between overlapping long-term conditions

The links between different long-term health conditions will be explored in new research funded with a £2.5million grant from the Medical Research Council.

New therapeutic targets identified in the treatment of psoriatic arthritis

Researchers identify two inflammatory-driving proteins, osteopontin and CCL2, highly expressed in psoriatic arthritis joints.

Researchers show the role of cilia in cartilage health

New research shows that disrupting primary cilia in juvenile, adolescent and early adulthood in cartilage stops it maturing correctly, making it more prone to thinning and the potential for osteoarthritis (OA) in later life.